CL2023002824A1 - Métodos y composiciones para tratar la apnea del sueño - Google Patents

Métodos y composiciones para tratar la apnea del sueño

Info

Publication number
CL2023002824A1
CL2023002824A1 CL2023002824A CL2023002824A CL2023002824A1 CL 2023002824 A1 CL2023002824 A1 CL 2023002824A1 CL 2023002824 A CL2023002824 A CL 2023002824A CL 2023002824 A CL2023002824 A CL 2023002824A CL 2023002824 A1 CL2023002824 A1 CL 2023002824A1
Authority
CL
Chile
Prior art keywords
methods
sleep apnea
compositions
treat sleep
antagonist
Prior art date
Application number
CL2023002824A
Other languages
English (en)
Inventor
G Miller Lawrence
Taranto-Montemurro Luigi
Farkas Ronald
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of CL2023002824A1 publication Critical patent/CL2023002824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se describen composiciones farmacéuticas que comprenden un inhibidor de la recaptación de norepinefrina (NRI) y un antagonista de mineralocorticoides y, opcionalmente, un antagonista del receptor muscarínico (MRA) y métodos para tratar la apnea del sueño.
CL2023002824A 2021-03-24 2023-09-22 Métodos y composiciones para tratar la apnea del sueño CL2023002824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163165342P 2021-03-24 2021-03-24

Publications (1)

Publication Number Publication Date
CL2023002824A1 true CL2023002824A1 (es) 2024-01-26

Family

ID=81388916

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002824A CL2023002824A1 (es) 2021-03-24 2023-09-22 Métodos y composiciones para tratar la apnea del sueño

Country Status (13)

Country Link
US (1) US20240173337A1 (es)
EP (1) EP4313153A1 (es)
JP (1) JP2024511091A (es)
KR (1) KR20230159462A (es)
CN (1) CN117062626A (es)
AU (1) AU2022245235A1 (es)
BR (1) BR112023019256A2 (es)
CA (1) CA3212035A1 (es)
CL (1) CL2023002824A1 (es)
CO (1) CO2023012587A2 (es)
CR (1) CR20230457A (es)
IL (1) IL307186A (es)
WO (1) WO2022204228A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049885A1 (en) * 2022-09-02 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152475A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN113692277A (zh) * 2019-02-08 2021-11-23 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
JP2023520455A (ja) * 2020-04-02 2023-05-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法および組成物

Also Published As

Publication number Publication date
CN117062626A (zh) 2023-11-14
JP2024511091A (ja) 2024-03-12
AU2022245235A1 (en) 2023-10-12
CO2023012587A2 (es) 2023-10-19
KR20230159462A (ko) 2023-11-21
EP4313153A1 (en) 2024-02-07
CR20230457A (es) 2024-02-19
US20240173337A1 (en) 2024-05-30
BR112023019256A2 (pt) 2023-10-17
WO2022204228A1 (en) 2022-09-29
IL307186A (en) 2023-11-01
CA3212035A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
CO2019013180A2 (es) Métodos y composiciones para el tratamiento de apnea del sueño
BR112014027860B8 (pt) Moduladores do transporte nuclear e usos dos mesmos
MX2020008086A (es) Metodos y composiciones para tratar la apnea del sue?o.
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
CO2023012587A2 (es) Métodos y composiciones para tratar la apnea del sueño
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
CO7310528A2 (es) Composición farmacéutica recubierta que contiene regorafenib
DOP2016000291A (es) Composiciones y métodos para modular la expresión del factor b del complemento
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
CR10540A (es) Derivados ciclopropil amina
CL2021003180A1 (es) Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico (divisional de solicitud n° 00723-2021)
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MY184048A (en) Arylsulfonamide ccr3 antagonists
CL2008003558A1 (es) Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga.
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CO2020003134A2 (es) Moduladores de la expresión de enac
BR112015001524A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de déficits cognitivos e uso de um composto